Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China.
Jing HuangHongnan MoWeilong ZhangXuelian ChenDong QuXi WangDawei WuXingyuan WangBo LanBeibei YangPei WangBo ZhangQing YangYuchen JiaoBinghe XuPublished in: Cancer (2018)
Anti-PD-1 antibody SHR-1210 shows encouraging efficacy in patients with advanced gastric/GEJ cancer in China, including mismatch repair-proficient subgroups.